Estudio especial; English Abstract; Journal Article;BACKGROUND In 1997, 18.5% of the cases of Meningococcal Disease caused b serogroup C in Andalusia were children between 2 and 4 years of age; ages where the initial immune response and the duration of the capsular A + C meningococcal polysaccharide vaccine is less than in older age groups. Research was designed in order to measure the immune response produced by this vaccine in children from 2 to 6 years of age and to compare it with the natural immunity present in unvaccinated children. METHODS I. Dual monitoring study: a) groups of children vaccinated previously and control groups, b) groups of children who were going to be vaccinated, for pre and post-vaccination (1, 6 and 12 months)...
Objective: To determine the persistence of bactericidal antibody titres following immunisation with ...
BACKGROUND: One schedule for the capsular group B meningococcal vaccine 4CMenB is 2 doses that are a...
Background: The multicomponent serogroup B meningococcal (4CMenB) vaccine was recently licensed for ...
Estudio especial; English Abstract; Journal Article;BACKGROUND In 1997, 18.5% of the cases of Mening...
Background: In 1997, 18.58 of the cases of Meningoxococcacal l Disease caused b serogroup C in Andal...
Background: An increase in the incidence of meningococcal disease in the Region of Murcia, Spain, du...
Contains fulltext : 88187.pdf (publisher's version ) (Open Access)BACKGROUND: In 2...
Background During a citywide epidemic of serogroup C meningococcal disease in Salvador in 2010, Braz...
BACKGROUND: The multicomponent serogroup B meningococcal (4CMenB) vaccine induces antibodies against...
BACKGROUND: Randomised trials carried out over two decades ago showed that the polysaccharide vaccin...
BACKGROUND:One schedule for the capsular group B meningococcal vaccine 4CMenB is 2 doses that are ad...
BACKGROUND: One schedule for the capsular group B meningococcal vaccine 4CMenB is 2 doses that are a...
CONTEXT: In the absence of an effective vaccine, serogroup B Neisseria meningitidis (MenB) remains a...
BACKGROUND: This report is a systematic review of the effect intensity and duration of the immune re...
BACKGROUND: The Self Governing Region of Cantabria within the state of Spain has a population of 541...
Objective: To determine the persistence of bactericidal antibody titres following immunisation with ...
BACKGROUND: One schedule for the capsular group B meningococcal vaccine 4CMenB is 2 doses that are a...
Background: The multicomponent serogroup B meningococcal (4CMenB) vaccine was recently licensed for ...
Estudio especial; English Abstract; Journal Article;BACKGROUND In 1997, 18.5% of the cases of Mening...
Background: In 1997, 18.58 of the cases of Meningoxococcacal l Disease caused b serogroup C in Andal...
Background: An increase in the incidence of meningococcal disease in the Region of Murcia, Spain, du...
Contains fulltext : 88187.pdf (publisher's version ) (Open Access)BACKGROUND: In 2...
Background During a citywide epidemic of serogroup C meningococcal disease in Salvador in 2010, Braz...
BACKGROUND: The multicomponent serogroup B meningococcal (4CMenB) vaccine induces antibodies against...
BACKGROUND: Randomised trials carried out over two decades ago showed that the polysaccharide vaccin...
BACKGROUND:One schedule for the capsular group B meningococcal vaccine 4CMenB is 2 doses that are ad...
BACKGROUND: One schedule for the capsular group B meningococcal vaccine 4CMenB is 2 doses that are a...
CONTEXT: In the absence of an effective vaccine, serogroup B Neisseria meningitidis (MenB) remains a...
BACKGROUND: This report is a systematic review of the effect intensity and duration of the immune re...
BACKGROUND: The Self Governing Region of Cantabria within the state of Spain has a population of 541...
Objective: To determine the persistence of bactericidal antibody titres following immunisation with ...
BACKGROUND: One schedule for the capsular group B meningococcal vaccine 4CMenB is 2 doses that are a...
Background: The multicomponent serogroup B meningococcal (4CMenB) vaccine was recently licensed for ...